Sun Pharma Shares Jump After Company's Quarterly Profit Rises Nearly 4 Times
Sun Pharmaceutical Industries shares jumped more than 4 per cent on Wednesday, a day after the drug maker reported strong quarterly earnings. The share price of Sun Pharma advanced as much as 4.2 per cent on the National Stock Exchange to touch Rs 455.00 in morning deals, compared with its closing price of Rs 436.60 the previous day. Sun Pharmaceutical Industries (Sun Pharma) shares traded with high volumes during Wednesday's session. At 10:54 am, Sun Pharma shares traded 1.5 per cent higher at Rs 443.30 on the bourse, outperforming the markets.
Sun Pharmaceutical Industries post-market hours on Tuesday reported a net profit of Rs 1,242 crore for the quarter ended December 31, 2018, as against Rs 322 crore for the corresponding period a year ago. Sun Pharma's net profit was better than analysts' estimates on strong sales in the US market. (Read:Â Sun Pharma posts nearly four-fold jump quarterly profit)
The pharma company said it had incurred a one-time tax expense of Rs 513 crore - related to changes in US tax rates - in the year-ago period.
Sun Pharma's sales in the US account for more than 34 per cent of its total sales. Sun Pharma said its India sales grew 7 per cent to Rs 2,235 crore, while US sales increased 10 per cent to $362 million.
The Sun Pharma shares' price has declined 35 per cent over the past five months.
As of 11 am, around 9.5 lakh Sun Pharma shares had changed hands on the Bombay Stock Exchange (BSE), compared with a two-week average of 5.6 lakh, stock exchange data showed.
Sun Pharma shares were among the top percentage gainers on benchmark indices Sensex and Nifty in morning.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
